factuality_value
stringclasses
7 values
predicat@xml:space
stringclasses
1 value
predicat@charOffset
stringlengths
3
9
predicat@headOffset
stringlengths
3
9
predicat@id
stringclasses
206 values
predicat@text
stringlengths
2
124
predicat@type
stringclasses
29 values
predicat@charOffsetMin
int64
0
3.96k
predicat@charOffsetMax
int64
6
3.97k
subject@xml:space
stringclasses
1 value
subject@charOffset
stringlengths
3
9
subject@headOffset
stringlengths
3
9
subject@id
stringclasses
197 values
subject@text
stringlengths
2
49
subject@type
stringclasses
72 values
subject@charOffsetMin
int64
0
3.98k
subject@charOffsetMax
int64
3
4k
object@xml:space
stringclasses
1 value
object@charOffset
stringlengths
3
9
object@headOffset
stringlengths
3
9
object@id
stringclasses
198 values
object@text
stringlengths
2
53
object@type
stringclasses
73 values
object@charOffsetMin
int64
0
3.93k
object@charOffsetMax
int64
4
3.94k
id
stringclasses
58 values
raw_sent_text
stringlengths
20
749
sent_charOffset
stringlengths
4
9
sent_charOffsetMin
int64
0
3.88k
sent_charOffsetMax
int64
26
4.2k
formated_sentence
stringlengths
34
768
Uncommitted
preserve
1360-1363
1360-1363
T72
for
TREATS
1,360
1,363
preserve
1208-1254
1244-1254
T66
angiotensin-converting enzyme inhibitors
PharmacologicSubstance
1,208
1,254
preserve
1364-1372
1364-1372
T70
patients
PatientOrDisabledGroup
1,364
1,372
A1
Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for patients with type 2 diabetes.
1138-1394
1,138
1,394
Therapy including aspirin, lipid agents (for example, statins), @SUBJECT$ , beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered @PREDICAT$ @OBJECT$ with type 2 diabetes.
Uncommitted
preserve
1360-1363
1360-1363
T72
for
TREATS
1,360
1,363
preserve
1329-1338
1337-1338
T69
vitamin E
Lipid
1,329
1,338
preserve
1364-1372
1364-1372
T70
patients
PatientOrDisabledGroup
1,364
1,372
A2
Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for patients with type 2 diabetes.
1138-1394
1,138
1,394
Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and @SUBJECT$ should be considered @PREDICAT$ @OBJECT$ with type 2 diabetes.
Fact
preserve
1528-1530
1528-1530
T91
to
higher_than
1,528
1,530
preserve
1478-1515
1507-1515
T84
coronary artery bypass grafting
TherapeuticOrPreventiveProcedure
1,478
1,515
preserve
1531-1551
1540-1551
T86
coronary angioplasty
TherapeuticOrPreventiveProcedure
1,531
1,551
A3
In most patients with diabetes who have multivessel coronary artery disease, coronary artery bypass grafting is superior to coronary angioplasty for improving long-term cardiovascular prognosis.
1395-1607
1,395
1,607
In most patients with diabetes who have multivessel coronary artery disease, @SUBJECT$ is superior @PREDICAT$ @OBJECT$ for improving long-term cardiovascular prognosis.
Uncommitted
preserve
1360-1363
1360-1363
T72
for
TREATS
1,360
1,363
preserve
1297-1317
1306-1317
T68
estrogen replacement
TherapeuticOrPreventiveProcedure
1,297
1,317
preserve
1364-1372
1364-1372
T70
patients
PatientOrDisabledGroup
1,364
1,372
A4
Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for patients with type 2 diabetes.
1138-1394
1,138
1,394
Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal @SUBJECT$ , and vitamin E should be considered @PREDICAT$ @OBJECT$ with type 2 diabetes.
Fact
preserve
101-105
101-105
T6
with
PROCESS_OF
101
105
preserve
106-114
106-114
T4
diabetes
DiseaseOrSyndrome
106
114
preserve
92-100
92-100
T3
patients
PatientOrDisabledGroup
92
100
A5
Approximately 80% of all patients with diabetes die of cardiovascular disease.
67-145
67
145
Approximately 80% of all @OBJECT$ @PREDICAT$ @SUBJECT$ die of cardiovascular disease.
Uncommitted
preserve
1360-1363
1360-1363
T72
for
TREATS
1,360
1,363
preserve
1256-1280
1272-1280
T67
beta-adrenergic blockers
PharmacologicSubstance
1,256
1,280
preserve
1364-1372
1364-1372
T70
patients
PatientOrDisabledGroup
1,364
1,372
A6
Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for patients with type 2 diabetes.
1138-1394
1,138
1,394
Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, @SUBJECT$ , postmenopausal estrogen replacement, and vitamin E should be considered @PREDICAT$ @OBJECT$ with type 2 diabetes.
Fact
preserve
1528-1530
1528-1530
T90
to
compared_with
1,528
1,530
preserve
1478-1515
1507-1515
T84
coronary artery bypass grafting
TherapeuticOrPreventiveProcedure
1,478
1,515
preserve
1531-1551
1540-1551
T86
coronary angioplasty
TherapeuticOrPreventiveProcedure
1,531
1,551
A7
In most patients with diabetes who have multivessel coronary artery disease, coronary artery bypass grafting is superior to coronary angioplasty for improving long-term cardiovascular prognosis.
1395-1607
1,395
1,607
In most patients with diabetes who have multivessel coronary artery disease, @SUBJECT$ is superior @PREDICAT$ @OBJECT$ for improving long-term cardiovascular prognosis.
Uncommitted
preserve
1830-1833
1830-1833
T108
for
TREATS
1,830
1,833
preserve
1757-1777
1766-1777
T103
coronary angioplasty
TherapeuticOrPreventiveProcedure
1,757
1,777
preserve
1838-1846
1838-1846
T105
patients
PatientOrDisabledGroup
1,838
1,846
A9
Urgent coronary angioplasty or thrombolytic therapy should be considered for all patients with diabetes who have acute myocardial infarction.
1750-1898
1,750
1,898
Urgent @SUBJECT$ or thrombolytic therapy should be considered @PREDICAT$ all @OBJECT$ with diabetes who have acute myocardial infarction.
Uncommitted
preserve
1830-1833
1830-1833
T108
for
TREATS
1,830
1,833
preserve
1757-1777
1766-1777
T103
coronary angioplasty
TherapeuticOrPreventiveProcedure
1,757
1,777
preserve
1852-1860
1852-1860
T106
diabetes
DiseaseOrSyndrome
1,852
1,860
A10
Urgent coronary angioplasty or thrombolytic therapy should be considered for all patients with diabetes who have acute myocardial infarction.
1750-1898
1,750
1,898
Urgent @SUBJECT$ or thrombolytic therapy should be considered @PREDICAT$ all patients with @OBJECT$ who have acute myocardial infarction.
Fact
preserve
1436-1440
1436-1440
T93
have
PROCESS_OF
1,436
1,440
preserve
1441-1476
1469-1476
T83
multivessel coronary artery disease
DiseaseOrSyndrome
1,441
1,476
preserve
1409-1417
1409-1417
T81
patients
PatientOrDisabledGroup
1,409
1,417
A11
In most patients with diabetes who have multivessel coronary artery disease, coronary artery bypass grafting is superior to coronary angioplasty for improving long-term cardiovascular prognosis.
1395-1607
1,395
1,607
In most @OBJECT$ with diabetes who @PREDICAT$ @SUBJECT$ , coronary artery bypass grafting is superior to coronary angioplasty for improving long-term cardiovascular prognosis.
Uncommitted
preserve
1360-1363
1360-1363
T72
for
TREATS
1,360
1,363
preserve
1329-1338
1337-1338
T69
vitamin E
Lipid
1,329
1,338
preserve
1378-1393
1385-1393
T71
type 2 diabetes
DiseaseOrSyndrome
1,378
1,393
A12
Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for patients with type 2 diabetes.
1138-1394
1,138
1,394
Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and @SUBJECT$ should be considered @PREDICAT$ patients with @OBJECT$ .
Fact
preserve
386-396
386-396
T25
associated
COEXISTS_WITH
386
396
preserve
529-548
539-548
T23
sedentary lifestyle
Finding
529
548
preserve
359-375
359-375
T15
hyperinsulinemia
DiseaseOrSyndrome
359
375
A14
Insulin resistance often leads to hyperinsulinemia, which is associated with hypertension, atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and sedentary lifestyle.
325-549
325
549
Insulin resistance often leads to @OBJECT$ , which is @PREDICAT$ with hypertension, atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and @SUBJECT$ .
Fact
preserve
386-396
386-396
T25
associated
COEXISTS_WITH
386
396
preserve
408-420
408-420
T16
hypertension
DiseaseOrSyndrome
408
420
preserve
359-375
359-375
T15
hyperinsulinemia
DiseaseOrSyndrome
359
375
A16
Insulin resistance often leads to hyperinsulinemia, which is associated with hypertension, atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and sedentary lifestyle.
325-549
325
549
Insulin resistance often leads to @OBJECT$ , which is @PREDICAT$ with @SUBJECT$ , atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and sedentary lifestyle.
Uncommitted
preserve
1360-1363
1360-1363
T72
for
TREATS
1,360
1,363
preserve
1297-1317
1306-1317
T68
estrogen replacement
TherapeuticOrPreventiveProcedure
1,297
1,317
preserve
1378-1393
1385-1393
T71
type 2 diabetes
DiseaseOrSyndrome
1,378
1,393
A17
Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for patients with type 2 diabetes.
1138-1394
1,138
1,394
Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal @SUBJECT$ , and vitamin E should be considered @PREDICAT$ patients with @OBJECT$ .
Fact
preserve
386-396
386-396
T25
associated
COEXISTS_WITH
386
396
preserve
434-446
434-446
T17
dyslipidemia
DiseaseOrSyndrome
434
446
preserve
359-375
359-375
T15
hyperinsulinemia
DiseaseOrSyndrome
359
375
A18
Insulin resistance often leads to hyperinsulinemia, which is associated with hypertension, atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and sedentary lifestyle.
325-549
325
549
Insulin resistance often leads to @OBJECT$ , which is @PREDICAT$ with hypertension, atherogenic @SUBJECT$ , left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and sedentary lifestyle.
Fact
preserve
1667-1694
1689-1694
T101
left internal mammary graft
PART_OF
1,667
1,694
preserve
1689-1694
1689-1694
T98
graft
Tissue
1,689
1,694
preserve
1667-1688
1681-1688
T97
left internal mammary
BodyPartOrganOrOrganComponent
1,667
1,688
A19
This superiority is mediated in part by the use of a left internal mammary graft to the left anterior descending coronary artery.
1608-1749
1,608
1,749
This superiority is mediated in part by the use of a @OBJECT$ @PREDICAT$ @SUBJECT$ to the left anterior descending coronary artery.
Fact
preserve
386-396
386-396
T25
associated
COEXISTS_WITH
386
396
preserve
448-476
465-476
T18
left ventricular hypertrophy
PathologicFunction
448
476
preserve
359-375
359-375
T15
hyperinsulinemia
DiseaseOrSyndrome
359
375
A20
Insulin resistance often leads to hyperinsulinemia, which is associated with hypertension, atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and sedentary lifestyle.
325-549
325
549
Insulin resistance often leads to @OBJECT$ , which is @PREDICAT$ with hypertension, atherogenic dyslipidemia, @SUBJECT$ , impaired fibrinolysis, visceral obesity, and sedentary lifestyle.
Uncommitted
preserve
1830-1833
1830-1833
T108
for
TREATS
1,830
1,833
preserve
1781-1801
1794-1801
T104
thrombolytic therapy
TherapeuticOrPreventiveProcedure
1,781
1,801
preserve
1838-1846
1838-1846
T105
patients
PatientOrDisabledGroup
1,838
1,846
A21
Urgent coronary angioplasty or thrombolytic therapy should be considered for all patients with diabetes who have acute myocardial infarction.
1750-1898
1,750
1,898
Urgent coronary angioplasty or @SUBJECT$ should be considered @PREDICAT$ all @OBJECT$ with diabetes who have acute myocardial infarction.
Fact
preserve
699-703
699-703
T41
with
PROCESS_OF
699
703
preserve
704-712
704-712
T36
diabetes
DiseaseOrSyndrome
704
712
preserve
690-698
690-698
T35
patients
PatientOrDisabledGroup
690
698
A22
Although all these conditions are associated with atherosclerosis and adverse cardiovascular events, the therapeutic efforts in patients with diabetes have focused predominantly on normalizing glucose levels.
550-776
550
776
Although all these conditions are associated with atherosclerosis and adverse cardiovascular events, the therapeutic efforts in @OBJECT$ @PREDICAT$ @SUBJECT$ have focused predominantly on normalizing glucose levels.
Fact
preserve
1847-1851
1847-1851
T110
with
PROCESS_OF
1,847
1,851
preserve
1852-1860
1852-1860
T106
diabetes
DiseaseOrSyndrome
1,852
1,860
preserve
1838-1846
1838-1846
T105
patients
PatientOrDisabledGroup
1,838
1,846
A23
Urgent coronary angioplasty or thrombolytic therapy should be considered for all patients with diabetes who have acute myocardial infarction.
1750-1898
1,750
1,898
Urgent coronary angioplasty or thrombolytic therapy should be considered for all @OBJECT$ @PREDICAT$ @SUBJECT$ who have acute myocardial infarction.
Probable
preserve
350-355
350-355
T24
leads
CAUSES
350
355
preserve
325-343
333-343
T13
Insulin resistance
PathologicFunction
325
343
preserve
359-375
359-375
T15
hyperinsulinemia
DiseaseOrSyndrome
359
375
A24
Insulin resistance often leads to hyperinsulinemia, which is associated with hypertension, atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and sedentary lifestyle.
325-549
325
549
@SUBJECT$ often @PREDICAT$ to @OBJECT$ , which is associated with hypertension, atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and sedentary lifestyle.
Uncommitted
preserve
1830-1833
1830-1833
T108
for
TREATS
1,830
1,833
preserve
1781-1801
1794-1801
T104
thrombolytic therapy
TherapeuticOrPreventiveProcedure
1,781
1,801
preserve
1852-1860
1852-1860
T106
diabetes
DiseaseOrSyndrome
1,852
1,860
A25
Urgent coronary angioplasty or thrombolytic therapy should be considered for all patients with diabetes who have acute myocardial infarction.
1750-1898
1,750
1,898
Urgent coronary angioplasty or @SUBJECT$ should be considered @PREDICAT$ all patients with @OBJECT$ who have acute myocardial infarction.
Fact
preserve
1418-1422
1418-1422
T92
with
PROCESS_OF
1,418
1,422
preserve
1423-1431
1423-1431
T82
diabetes
DiseaseOrSyndrome
1,423
1,431
preserve
1409-1417
1409-1417
T81
patients
PatientOrDisabledGroup
1,409
1,417
A26
In most patients with diabetes who have multivessel coronary artery disease, coronary artery bypass grafting is superior to coronary angioplasty for improving long-term cardiovascular prognosis.
1395-1607
1,395
1,607
In most @OBJECT$ @PREDICAT$ @SUBJECT$ who have multivessel coronary artery disease, coronary artery bypass grafting is superior to coronary angioplasty for improving long-term cardiovascular prognosis.
Fact
preserve
386-396
386-396
T25
associated
COEXISTS_WITH
386
396
preserve
516-523
516-523
T22
obesity
DiseaseOrSyndrome
516
523
preserve
359-375
359-375
T15
hyperinsulinemia
DiseaseOrSyndrome
359
375
A27
Insulin resistance often leads to hyperinsulinemia, which is associated with hypertension, atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral obesity, and sedentary lifestyle.
325-549
325
549
Insulin resistance often leads to @OBJECT$ , which is @PREDICAT$ with hypertension, atherogenic dyslipidemia, left ventricular hypertrophy, impaired fibrinolysis, visceral @SUBJECT$ , and sedentary lifestyle.
Uncommitted
preserve
1360-1363
1360-1363
T72
for
TREATS
1,360
1,363
preserve
1256-1280
1272-1280
T67
beta-adrenergic blockers
PharmacologicSubstance
1,256
1,280
preserve
1378-1393
1385-1393
T71
type 2 diabetes
DiseaseOrSyndrome
1,378
1,393
A28
Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for patients with type 2 diabetes.
1138-1394
1,138
1,394
Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, @SUBJECT$ , postmenopausal estrogen replacement, and vitamin E should be considered @PREDICAT$ patients with @OBJECT$ .
Fact
preserve
1373-1377
1373-1377
T76
with
PROCESS_OF
1,373
1,377
preserve
1378-1393
1385-1393
T71
type 2 diabetes
DiseaseOrSyndrome
1,378
1,393
preserve
1364-1372
1364-1372
T70
patients
PatientOrDisabledGroup
1,364
1,372
A29
Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for patients with type 2 diabetes.
1138-1394
1,138
1,394
Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for @OBJECT$ @PREDICAT$ @SUBJECT$ .
Uncommitted
preserve
1360-1363
1360-1363
T72
for
TREATS
1,360
1,363
preserve
1208-1254
1244-1254
T66
angiotensin-converting enzyme inhibitors
PharmacologicSubstance
1,208
1,254
preserve
1378-1393
1385-1393
T71
type 2 diabetes
DiseaseOrSyndrome
1,378
1,393
A30
Therapy including aspirin, lipid agents (for example, statins), angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered for patients with type 2 diabetes.
1138-1394
1,138
1,394
Therapy including aspirin, lipid agents (for example, statins), @SUBJECT$ , beta-adrenergic blockers, postmenopausal estrogen replacement, and vitamin E should be considered @PREDICAT$ patients with @OBJECT$ .
Fact
preserve
1616-1618
1616-1618
T84
in
TREATS
1,616
1,618
preserve
1606-1615
1606-1615
T81
therapies
TherapeuticOrPreventiveProcedure
1,606
1,615
preserve
1633-1646
1639-1646
T83
heart failure
DiseaseOrSyndrome
1,633
1,646
A1
The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with ACE inhibitors and all other prescribed therapies in patients with heart failure.
1384-1647
1,384
1,647
The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with ACE inhibitors and all other prescribed @SUBJECT$ @PREDICAT$ patients with @OBJECT$ .
Fact
preserve
1616-1618
1616-1618
T84
in
TREATS
1,616
1,618
preserve
1560-1574
1564-1574
T79
ACE inhibitors
PharmacologicSubstance
1,560
1,574
preserve
1633-1646
1639-1646
T83
heart failure
DiseaseOrSyndrome
1,633
1,646
A2
The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with ACE inhibitors and all other prescribed therapies in patients with heart failure.
1384-1647
1,384
1,647
The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with @SUBJECT$ and all other prescribed therapies @PREDICAT$ patients with @OBJECT$ .
Fact
preserve
1343-1353
1343-1353
T70
inhibition
DISRUPTS
1,343
1,353
preserve
1333-1336
1333-1336
T66
ACE
AminoAcidPeptideOrProtein
1,333
1,336
preserve
1285-1301
1285-1301
T63
vasoconstriction
OrganOrTissueFunction
1,285
1,301
A3
Persistent angiotensin-induced vasoconstriction and endocrine effects, despite ACE inhibition, is one possible explanation.
1248-1383
1,248
1,383
Persistent angiotensin-induced @OBJECT$ and endocrine effects, despite @SUBJECT$ @PREDICAT$ , is one possible explanation.
Fact
preserve
1628-1632
1628-1632
T86
with
PROCESS_OF
1,628
1,632
preserve
1633-1646
1639-1646
T83
heart failure
DiseaseOrSyndrome
1,633
1,646
preserve
1619-1627
1619-1627
T82
patients
PatientOrDisabledGroup
1,619
1,627
A4
The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with ACE inhibitors and all other prescribed therapies in patients with heart failure.
1384-1647
1,384
1,647
The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with ACE inhibitors and all other prescribed therapies in @OBJECT$ @PREDICAT$ @SUBJECT$ .
Fact
preserve
1616-1618
1616-1618
T84
in
TREATS
1,616
1,618
preserve
1560-1574
1564-1574
T79
ACE inhibitors
PharmacologicSubstance
1,560
1,574
preserve
1619-1627
1619-1627
T82
patients
PatientOrDisabledGroup
1,619
1,627
A5
The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with ACE inhibitors and all other prescribed therapies in patients with heart failure.
1384-1647
1,384
1,647
The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with @SUBJECT$ and all other prescribed therapies @PREDICAT$ @OBJECT$ with heart failure.
Fact
preserve
1188-1246
1188-1197
T58
magnitude of these benefits has been disappointingly small
ISA
1,188
1,246
preserve
1241-1246
1241-1246
T57
small
QuantitativeConcept
1,241
1,246
preserve
1188-1197
1188-1197
T55
magnitude
QuantitativeConcept
1,188
1,197
A6
Angiotensin-converting enzyme (ACE) inhibitors have exerted favorable effects on both quality of life and mortality, but the magnitude of these benefits has been disappointingly small.
1051-1247
1,051
1,247
Angiotensin-converting enzyme (ACE) inhibitors have exerted favorable effects on both quality of life and mortality, but the @OBJECT$ @PREDICAT$ @SUBJECT$ .
Probable
preserve
999-1005
999-1005
T49
reduce
PREVENTS
999
1,005
preserve
989-994
989-994
T46
drugs
PharmacologicSubstance
989
994
preserve
1006-1014
1006-1014
T47
symptoms
SignOrSymptom
1,006
1,014
A7
Certain inotropic drugs may reduce symptoms but shorten life expectancy.
971-1050
971
1,050
Certain inotropic @SUBJECT$ may @PREDICAT$ @OBJECT$ but shorten life expectancy.
Fact
preserve
1616-1618
1616-1618
T84
in
TREATS
1,616
1,618
preserve
1606-1615
1606-1615
T81
therapies
TherapeuticOrPreventiveProcedure
1,606
1,615
preserve
1619-1627
1619-1627
T82
patients
PatientOrDisabledGroup
1,619
1,627
A9
The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with ACE inhibitors and all other prescribed therapies in patients with heart failure.
1384-1647
1,384
1,647
The Valsartan in Heart Failure Trial (Val-HeFT) has been designed to test the efficacy and safety of the AT(1) receptor blocker (ARB) valsartan in combination with ACE inhibitors and all other prescribed @SUBJECT$ @PREDICAT$ @OBJECT$ with heart failure.
Fact
preserve
2214-2223
2214-2223
T133
treatment
TREATS
2,214
2,223
preserve
2196-2209
2200-2209
T128
ACE inhibitor
PharmacologicSubstance
2,196
2,209
preserve
2227-2240
2233-2240
T130
heart failure
DiseaseOrSyndrome
2,227
2,240
A2
High doses of angiotensin-converting enzyme (ACE) inhibitors should be reserved for dialysis patients who have hypertension that cannot be controlled by other agents, or who require an ACE inhibitor for treatment of heart failure.
1992-2241
1,992
2,241
High doses of angiotensin-converting enzyme (ACE) inhibitors should be reserved for dialysis patients who have hypertension that cannot be controlled by other agents, or who require an @SUBJECT$ for @PREDICAT$ of @OBJECT$ .
Fact
preserve
1570-1574
1570-1574
T99
with
PROCESS_OF
1,570
1,574
preserve
1575-1582
1575-1582
T90
anaemia
DiseaseOrSyndrome
1,575
1,582
preserve
1561-1569
1561-1569
T89
patients
PatientOrDisabledGroup
1,561
1,569
A3
L-Carnitine supplementation may be appropriate in some patients with anaemia of chronic renal failure (CRF) unresponsive to, or requiring large doses of, epoetin.
1500-1674
1,500
1,674
L-Carnitine supplementation may be appropriate in some @OBJECT$ @PREDICAT$ @SUBJECT$ of chronic renal failure (CRF) unresponsive to, or requiring large doses of, epoetin.
Fact
preserve
2110-2114
2110-2114
T132
have
PROCESS_OF
2,110
2,114
preserve
2115-2127
2115-2127
T126
hypertension
DiseaseOrSyndrome
2,115
2,127
preserve
2097-2105
2097-2105
T125
patients
PatientOrDisabledGroup
2,097
2,105
A4
High doses of angiotensin-converting enzyme (ACE) inhibitors should be reserved for dialysis patients who have hypertension that cannot be controlled by other agents, or who require an ACE inhibitor for treatment of heart failure.
1992-2241
1,992
2,241
High doses of angiotensin-converting enzyme (ACE) inhibitors should be reserved for dialysis @OBJECT$ who @PREDICAT$ @SUBJECT$ that cannot be controlled by other agents, or who require an ACE inhibitor for treatment of heart failure.
Fact
preserve
1978-1990
1982-1990
T119
CRF patients
PROCESS_OF
1,978
1,990
preserve
1978-1981
1978-1981
T117
CRF
DiseaseOrSyndrome
1,978
1,981
preserve
1982-1990
1982-1990
T118
patients
PatientOrDisabledGroup
1,982
1,990
A6
Recent animal studies indicate that the combination of epoetin and insulin-like growth factor 1 might be beneficial in CRF patients.
1847-1991
1,847
1,991
Recent animal studies indicate that the combination of epoetin and insulin-like growth factor 1 might be beneficial in @SUBJECT$ @PREDICAT$ @OBJECT$ .
Fact
preserve
1500-1533
1518-1533
T97
L-Carnitine supplementation
USES
1,500
1,533
preserve
1518-1533
1518-1533
T87
supplementation
TherapeuticOrPreventiveProcedure
1,518
1,533
preserve
1500-1511
1500-1511
T86
L-Carnitine
OrganicChemical
1,500
1,511
A8
L-Carnitine supplementation may be appropriate in some patients with anaemia of chronic renal failure (CRF) unresponsive to, or requiring large doses of, epoetin.
1500-1674
1,500
1,674
@OBJECT$ @PREDICAT$ @SUBJECT$ may be appropriate in some patients with anaemia of chronic renal failure (CRF) unresponsive to, or requiring large doses of, epoetin.
Fact
preserve
355-364
355-364
T26
receiving
ADMINISTERED_TO
355
364
preserve
365-372
365-372
T24
epoetin
AminoAcidPeptideOrProtein
365
372
preserve
346-354
346-354
T23
patients
PatientOrDisabledGroup
346
354
A9
Iron supplementation is currently the most widely used form of adjuvant therapy; intravenous (i.v.) iron is required by the majority of haemodialysis patients receiving epoetin.
184-373
184
373
Iron supplementation is currently the most widely used form of adjuvant therapy; intravenous (i.v.) iron is required by the majority of haemodialysis @OBJECT$ @PREDICAT$ @SUBJECT$ .
Possible
preserve
1975-1977
1975-1977
T120
in
TREATS
1,975
1,977
preserve
1908-1915
1908-1915
T115
epoetin
AminoAcidPeptideOrProtein
1,908
1,915
preserve
1982-1990
1982-1990
T118
patients
PatientOrDisabledGroup
1,982
1,990
A10
Recent animal studies indicate that the combination of epoetin and insulin-like growth factor 1 might be beneficial in CRF patients.
1847-1991
1,847
1,991
Recent animal studies indicate that the combination of @SUBJECT$ and insulin-like growth factor 1 might be beneficial @PREDICAT$ CRF @OBJECT$ .
Fact
preserve
1017-1032
1025-1032
T66
epoetin therapy
ISA
1,017
1,032
preserve
1017-1024
1017-1024
T61
epoetin
AminoAcidPeptideOrProtein
1,017
1,024
preserve
1025-1032
1025-1032
T62
therapy
TherapeuticOrPreventiveProcedure
1,025
1,032
A11
Vitamin B6 requirements are increased during epoetin therapy, and supplementation at a dose of 100-150 mg/week is recommended.
965-1098
965
1,098
Vitamin B6 requirements are increased during @SUBJECT$ @PREDICAT$ @OBJECT$ , and supplementation at a dose of 100-150 mg/week is recommended.
Possible
preserve
903-910
903-910
T57
improve
TREATS
903
910
preserve
844-856
844-856
T51
alfacalcidol
PharmacologicSubstance
844
856
preserve
911-918
911-918
T53
anaemia
DiseaseOrSyndrome
911
918
A12
The active vitamin D metabolites alfacalcidol and calcitriol may, under some circumstances, improve anaemia and reduce epoetin dosage requirements.
805-964
805
964
The active vitamin D metabolites @SUBJECT$ and calcitriol may, under some circumstances, @PREDICAT$ @OBJECT$ and reduce epoetin dosage requirements.
Fact
preserve
119-126
119-126
T12
treated
TREATS
119
126
preserve
132-139
132-139
T8
epoetin
AminoAcidPeptideOrProtein
132
139
preserve
104-112
104-112
T7
patients
PatientOrDisabledGroup
104
112
A13
Adjuvant therapy may allow patients being treated with epoetin to derive greater clinical benefits.
77-183
77
183
Adjuvant therapy may allow @OBJECT$ being @PREDICAT$ with @SUBJECT$ to derive greater clinical benefits.
Fact
preserve
2078-2081
2078-2081
T131
for
TREATS
2,078
2,081
preserve
2012-2058
2048-2058
T123
angiotensin-converting enzyme (ACE) inhibitors
PharmacologicSubstance
2,012
2,058
preserve
2115-2127
2115-2127
T126
hypertension
DiseaseOrSyndrome
2,115
2,127
A14
High doses of angiotensin-converting enzyme (ACE) inhibitors should be reserved for dialysis patients who have hypertension that cannot be controlled by other agents, or who require an ACE inhibitor for treatment of heart failure.
1992-2241
1,992
2,241
High doses of @SUBJECT$ should be reserved @PREDICAT$ dialysis patients who have @OBJECT$ that cannot be controlled by other agents, or who require an ACE inhibitor for treatment of heart failure.
Fact
preserve
2078-2081
2078-2081
T131
for
TREATS
2,078
2,081
preserve
2012-2058
2048-2058
T123
angiotensin-converting enzyme (ACE) inhibitors
PharmacologicSubstance
2,012
2,058
preserve
2097-2105
2097-2105
T125
patients
PatientOrDisabledGroup
2,097
2,105
A15
High doses of angiotensin-converting enzyme (ACE) inhibitors should be reserved for dialysis patients who have hypertension that cannot be controlled by other agents, or who require an ACE inhibitor for treatment of heart failure.
1992-2241
1,992
2,241
High doses of @SUBJECT$ should be reserved @PREDICAT$ dialysis @OBJECT$ who have hypertension that cannot be controlled by other agents, or who require an ACE inhibitor for treatment of heart failure.
Probable
preserve
1553-1555
1553-1555
T98
in
TREATS
1,553
1,555
preserve
1518-1533
1518-1533
T87
supplementation
TherapeuticOrPreventiveProcedure
1,518
1,533
preserve
1561-1569
1561-1569
T89
patients
PatientOrDisabledGroup
1,561
1,569
A16
L-Carnitine supplementation may be appropriate in some patients with anaemia of chronic renal failure (CRF) unresponsive to, or requiring large doses of, epoetin.
1500-1674
1,500
1,674
L-Carnitine @SUBJECT$ may be appropriate @PREDICAT$ some @OBJECT$ with anaemia of chronic renal failure (CRF) unresponsive to, or requiring large doses of, epoetin.
Uncommitted
preserve
37-39
37-39
T5
in
TREATS
37
39
preserve
20-36
29-36
T2
adjuvant therapy
TherapeuticOrPreventiveProcedure
20
36
preserve
40-48
40-48
T3
patients
PatientOrDisabledGroup
40
48
A17
Is there a role for adjuvant therapy in patients being treated with epoetin?
0-76
0
76
Is there a role for @SUBJECT$ @PREDICAT$ @OBJECT$ being treated with epoetin?
Probable
preserve
1553-1555
1553-1555
T98
in
TREATS
1,553
1,555
preserve
1518-1533
1518-1533
T87
supplementation
TherapeuticOrPreventiveProcedure
1,518
1,533
preserve
1575-1582
1575-1582
T90
anaemia
DiseaseOrSyndrome
1,575
1,582
A18
L-Carnitine supplementation may be appropriate in some patients with anaemia of chronic renal failure (CRF) unresponsive to, or requiring large doses of, epoetin.
1500-1674
1,500
1,674
L-Carnitine @SUBJECT$ may be appropriate @PREDICAT$ some patients with @OBJECT$ of chronic renal failure (CRF) unresponsive to, or requiring large doses of, epoetin.
Fact
preserve
184-204
189-204
T25
Iron supplementation
USES
184
204
preserve
189-204
189-204
T14
supplementation
TherapeuticOrPreventiveProcedure
189
204
preserve
184-188
184-188
T13
Iron
BiologicallyActiveSubstance
184
188
A19
Iron supplementation is currently the most widely used form of adjuvant therapy; intravenous (i.v.) iron is required by the majority of haemodialysis patients receiving epoetin.
184-373
184
373
@OBJECT$ @PREDICAT$ @SUBJECT$ is currently the most widely used form of adjuvant therapy; intravenous (i.v.) iron is required by the majority of haemodialysis patients receiving epoetin.
Fact
preserve
1472-1476
1472-1476
T85
with
PROCESS_OF
1,472
1,476
preserve
1477-1498
1477-1498
T83
hyperhomocysteinaemia
DiseaseOrSyndrome
1,477
1,498
preserve
1463-1471
1463-1471
T82
patients
PatientOrDisabledGroup
1,463
1,471
A20
Low doses (2-3 mg/week) should normally be sufficient to maintain optimal folic acid stores in epoetin-treated patients, although higher doses are necessary for patients with hyperhomocysteinaemia.
1290-1499
1,290
1,499
Low doses (2-3 mg/week) should normally be sufficient to maintain optimal folic acid stores in epoetin-treated patients, although higher doses are necessary for @OBJECT$ @PREDICAT$ @SUBJECT$ .
Possible
preserve
903-910
903-910
T57
improve
TREATS
903
910
preserve
861-871
861-871
T52
calcitriol
Hormone
861
871
preserve
911-918
911-918
T53
anaemia
DiseaseOrSyndrome
911
918
A21
The active vitamin D metabolites alfacalcidol and calcitriol may, under some circumstances, improve anaemia and reduce epoetin dosage requirements.
805-964
805
964
The active vitamin D metabolites alfacalcidol and @SUBJECT$ may, under some circumstances, @PREDICAT$ @OBJECT$ and reduce epoetin dosage requirements.
Possible
preserve
1975-1977
1975-1977
T120
in
TREATS
1,975
1,977
preserve
1908-1915
1908-1915
T115
epoetin
AminoAcidPeptideOrProtein
1,908
1,915
preserve
1978-1981
1978-1981
T117
CRF
DiseaseOrSyndrome
1,978
1,981
A22
Recent animal studies indicate that the combination of epoetin and insulin-like growth factor 1 might be beneficial in CRF patients.
1847-1991
1,847
1,991
Recent animal studies indicate that the combination of @SUBJECT$ and insulin-like growth factor 1 might be beneficial @PREDICAT$ @OBJECT$ patients.
Fact
preserve
1824-1828
1824-1828
T111
with
PROCESS_OF
1,824
1,828
preserve
1839-1845
1839-1845
T109
kidney
ClinicalAttribute
1,839
1,845
preserve
1800-1803
1800-1803
T106
men
PopulationGroup
1,800
1,803
A23
Androgens potentially could reduce epoetin costs in countries with limited resources, but should only be used in men older than 50 years with a remnant kidney.
1675-1846
1,675
1,846
Androgens potentially could reduce epoetin costs in countries with limited resources, but should only be used in @OBJECT$ older than 50 years @PREDICAT$ a remnant @SUBJECT$ .
Fact
preserve
716-718
716-718
T43
in
TREATS
716
718
preserve
687-694
687-694
T38
therapy
TherapeuticOrPreventiveProcedure
687
694
preserve
739-749
747-749
T41
Type II DM
DiseaseOrSyndrome
739
749
A2
This 11-year study is comparing conventional therapy to intensive therapy in patients with Type II DM.
636-750
636
750
This 11-year study is comparing conventional @SUBJECT$ to intensive therapy @PREDICAT$ patients with @OBJECT$ .
Fact
preserve
907-916
907-916
T63
treatment
TREATS
907
916
preserve
867-874
867-874
T54
insulin
AminoAcidPeptideOrProtein
867
874
preserve
921-931
929-931
T58
Type II DM
DiseaseOrSyndrome
921
931
A3
The American Diabetes Association's (ADA) guidelines state that either sulfonylureas, metformin, acarbose, or insulin can be used as first-line treatment for Type II DM; however, oral agents can be attempted first in most patients.
751-1000
751
1,000
The American Diabetes Association's (ADA) guidelines state that either sulfonylureas, metformin, acarbose, or @SUBJECT$ can be used as first-line @PREDICAT$ for @OBJECT$ ; however, oral agents can be attempted first in most patients.
Fact
preserve
716-718
716-718
T43
in
TREATS
716
718
preserve
708-715
708-715
T39
therapy
TherapeuticOrPreventiveProcedure
708
715
preserve
719-727
719-727
T40
patients
PatientOrDisabledGroup
719
727
A4
This 11-year study is comparing conventional therapy to intensive therapy in patients with Type II DM.
636-750
636
750
This 11-year study is comparing conventional therapy to intensive @SUBJECT$ @PREDICAT$ @OBJECT$ with Type II DM.
Fact
preserve
907-916
907-916
T63
treatment
TREATS
907
916
preserve
843-852
843-852
T52
metformin
OrganicChemical
843
852
preserve
921-931
929-931
T58
Type II DM
DiseaseOrSyndrome
921
931
A5
The American Diabetes Association's (ADA) guidelines state that either sulfonylureas, metformin, acarbose, or insulin can be used as first-line treatment for Type II DM; however, oral agents can be attempted first in most patients.
751-1000
751
1,000
The American Diabetes Association's (ADA) guidelines state that either sulfonylureas, @SUBJECT$ , acarbose, or insulin can be used as first-line @PREDICAT$ for @OBJECT$ ; however, oral agents can be attempted first in most patients.
Fact
preserve
716-718
716-718
T43
in
TREATS
716
718
preserve
708-715
708-715
T39
therapy
TherapeuticOrPreventiveProcedure
708
715
preserve
739-749
747-749
T41
Type II DM
DiseaseOrSyndrome
739
749
A6
This 11-year study is comparing conventional therapy to intensive therapy in patients with Type II DM.
636-750
636
750
This 11-year study is comparing conventional therapy to intensive @SUBJECT$ @PREDICAT$ patients with @OBJECT$ .
Fact
preserve
728-732
728-732
T45
with
PROCESS_OF
728
732
preserve
739-749
747-749
T41
Type II DM
DiseaseOrSyndrome
739
749
preserve
719-727
719-727
T40
patients
PatientOrDisabledGroup
719
727
A7
This 11-year study is comparing conventional therapy to intensive therapy in patients with Type II DM.
636-750
636
750
This 11-year study is comparing conventional therapy to intensive therapy in @OBJECT$ @PREDICAT$ @SUBJECT$ .
Fact
preserve
506-510
506-510
T30
with
PROCESS_OF
506
510
preserve
511-521
519-521
T29
Type II DM
DiseaseOrSyndrome
511
521
preserve
497-505
497-505
T28
patients
PatientOrDisabledGroup
497
505
A8
Still, the current standard of practice is to attempt to attain glycemic goals in patients with Type II DM.
409-522
409
522
Still, the current standard of practice is to attempt to attain glycemic goals in @OBJECT$ @PREDICAT$ @SUBJECT$ .
Fact
preserve
907-916
907-916
T63
treatment
TREATS
907
916
preserve
828-841
828-841
T51
sulfonylureas
OrganicChemical
828
841
preserve
921-931
929-931
T58
Type II DM
DiseaseOrSyndrome
921
931
A9
The American Diabetes Association's (ADA) guidelines state that either sulfonylureas, metformin, acarbose, or insulin can be used as first-line treatment for Type II DM; however, oral agents can be attempted first in most patients.
751-1000
751
1,000
The American Diabetes Association's (ADA) guidelines state that either @SUBJECT$ , metformin, acarbose, or insulin can be used as first-line @PREDICAT$ for @OBJECT$ ; however, oral agents can be attempted first in most patients.
Fact
preserve
316-318
316-318
T22
in
COEXISTS_WITH
316
318
preserve
268-281
268-281
T14
complications
PathologicFunction
268
281
preserve
319-329
327-329
T17
Type II DM
DiseaseOrSyndrome
319
329
A10
Currently, no data exist showing improved outcomes or reduced macrovascular complications with tight glycemic control in Type II DM, and only minimal data shows a reduction of microvascular complications.
186-408
186
408
Currently, no data exist showing improved outcomes or reduced macrovascular @SUBJECT$ with tight glycemic control @PREDICAT$ @OBJECT$ , and only minimal data shows a reduction of microvascular complications.
Fact
preserve
664-673
664-673
T42
comparing
compared_with
664
673
preserve
687-694
687-694
T38
therapy
TherapeuticOrPreventiveProcedure
687
694
preserve
708-715
708-715
T39
therapy
TherapeuticOrPreventiveProcedure
708
715
A11
This 11-year study is comparing conventional therapy to intensive therapy in patients with Type II DM.
636-750
636
750
This 11-year study is @PREDICAT$ conventional @SUBJECT$ to intensive @OBJECT$ in patients with Type II DM.
Fact
preserve
907-916
907-916
T63
treatment
TREATS
907
916
preserve
854-862
854-862
T53
acarbose
Carbohydrate
854
862
preserve
921-931
929-931
T58
Type II DM
DiseaseOrSyndrome
921
931
A12
The American Diabetes Association's (ADA) guidelines state that either sulfonylureas, metformin, acarbose, or insulin can be used as first-line treatment for Type II DM; however, oral agents can be attempted first in most patients.
751-1000
751
1,000
The American Diabetes Association's (ADA) guidelines state that either sulfonylureas, metformin, @SUBJECT$ , or insulin can be used as first-line @PREDICAT$ for @OBJECT$ ; however, oral agents can be attempted first in most patients.
Fact
preserve
716-718
716-718
T43
in
TREATS
716
718
preserve
687-694
687-694
T38
therapy
TherapeuticOrPreventiveProcedure
687
694
preserve
719-727
719-727
T40
patients
PatientOrDisabledGroup
719
727
A13
This 11-year study is comparing conventional therapy to intensive therapy in patients with Type II DM.
636-750
636
750
This 11-year study is comparing conventional @SUBJECT$ to intensive therapy @PREDICAT$ @OBJECT$ with Type II DM.
Fact
preserve
2052-2073
2066-2073
T106
antibacterial therapy
USES
2,052
2,073
preserve
2066-2073
2066-2073
T103
therapy
TherapeuticOrPreventiveProcedure
2,066
2,073
preserve
2052-2065
2052-2065
T102
antibacterial
Antibiotic
2,052
2,065
A2
Future large-scale clinical trials are needed to further evaluate the evidence of causality and the efficacy of antibacterial therapy for coronary artery disease.
1926-2102
1,926
2,102
Future large-scale clinical trials are needed to further evaluate the evidence of causality and the efficacy of @OBJECT$ @PREDICAT$ @SUBJECT$ for coronary artery disease.
Possible
preserve
357-365
357-365
T25
modulate
AFFECTS
357
365
preserve
323-340
331-340
T20
chronic infection
DiseaseOrSyndrome
323
340
preserve
378-387
378-387
T21
processes
PhenomenonOrProcess
378
387
A3
With this awareness, the possibility that acute or chronic infection may initiate or modulate these processes in an active area of investigation.
266-423
266
423
With this awareness, the possibility that acute or @SUBJECT$ may initiate or @PREDICAT$ these @OBJECT$ in an active area of investigation.
Fact
preserve
1626-1649
1640-1649
T89
antibacterial treatment
USES
1,626
1,649
preserve
1640-1649
1640-1649
T83
treatment
TherapeuticOrPreventiveProcedure
1,640
1,649
preserve
1626-1639
1626-1639
T82
antibacterial
Antibiotic
1,626
1,639
A4
Finally, recent pilot trials have demonstrated that macrolide antibacterial treatment directed against C. pneumoniae reduces the risk of recurrent coronary events.
1558-1733
1,558
1,733
Finally, recent pilot trials have demonstrated that macrolide @OBJECT$ @PREDICAT$ @SUBJECT$ directed against C. pneumoniae reduces the risk of recurrent coronary events.
Fact
preserve
1330-1353
1346-1353
T71
coronary artery plaques
LOCATION_OF
1,330
1,353
preserve
1330-1345
1339-1345
T69
coronary artery
BodyPartOrganOrOrganComponent
1,330
1,345
preserve
1346-1353
1346-1353
T70
plaques
AcquiredAbnormality
1,346
1,353
A5
In addition, pathological examinations have demonstrated the presence of infectious organisms in coronary artery plaques.
1227-1354
1,227
1,354
In addition, pathological examinations have demonstrated the presence of infectious organisms in @SUBJECT$ @PREDICAT$ @OBJECT$ .
Possible
preserve
50-54
50-54
T9
role
AFFECTS
50
54
preserve
58-67
58-67
T6
infection
DiseaseOrSyndrome
58
67
preserve
77-90
77-90
T7
atherogenesis
PathologicFunction
77
90
A6
A possible role of infection in atherogenesis and acute coronary syndromes.
39-120
39
120
A possible @PREDICAT$ of @SUBJECT$ in @OBJECT$ and acute coronary syndromes.
Uncommitted
preserve
12-15
12-15
T3
for
TREATS
12
15
preserve
0-11
0-11
T1
Antibiotics
Antibiotic
0
11
preserve
16-37
27-37
T2
myocardial infarction
DiseaseOrSyndrome
16
37
A7
Antibiotics for myocardial infarction?
0-38
0
38
@SUBJECT$ @PREDICAT$ @OBJECT$ ?
Possible
preserve
50-54
50-54
T9
role
AFFECTS
50
54
preserve
58-67
58-67
T6
infection
DiseaseOrSyndrome
58
67
preserve
95-119
110-119
T8
acute coronary syndromes
DiseaseOrSyndrome
95
119
A8
A possible role of infection in atherogenesis and acute coronary syndromes.
39-120
39
120
A possible @PREDICAT$ of @SUBJECT$ in atherogenesis and @OBJECT$ .
Fact
preserve
2066-2073
2066-2073
T107
therapy
TREATS
2,066
2,073
preserve
2052-2065
2052-2065
T102
antibacterial
Antibiotic
2,052
2,065
preserve
2078-2101
2094-2101
T104
coronary artery disease
DiseaseOrSyndrome
2,078
2,101
A9
Future large-scale clinical trials are needed to further evaluate the evidence of causality and the efficacy of antibacterial therapy for coronary artery disease.
1926-2102
1,926
2,102
Future large-scale clinical trials are needed to further evaluate the evidence of causality and the efficacy of @SUBJECT$ @PREDICAT$ for @OBJECT$ .
Fact
preserve
561-589
584-589
T39
vascular smooth muscle cells
PART_OF
561
589
preserve
570-589
584-589
T35
smooth muscle cells
Cell
570
589
preserve
561-569
561-569
T34
vascular
BodyPartOrganOrOrganComponent
561
569
A10
Infectious organisms may influence the atherosclerotic process through direct local effects on the coronary endothelium, on vascular smooth muscle cells and on macrophages in the atherosclerotic lesion.
424-645
424
645
Infectious organisms may influence the atherosclerotic process through direct local effects on the coronary endothelium, on @OBJECT$ @PREDICAT$ @SUBJECT$ and on macrophages in the atherosclerotic lesion.
Fact
preserve
894-897
894-897
T59
had
PROCESS_OF
894
897
preserve
898-909
902-909
T58
hot flashes
SignOrSymptom
898
909
preserve
879-887
879-887
T57
patients
PatientOrDisabledGroup
879
887
A1
Fourteen patients (66%) had hot flashes.
870-910
870
910
Fourteen @OBJECT$ (66%) @PREDICAT$ @SUBJECT$ .
Fact
preserve
431-433
431-433
T37
in
PROCESS_OF
431
433
preserve
420-430
420-430
T30
depression
Finding
420
430
preserve
443-451
443-451
T31
patients
PatientOrDisabledGroup
443
451
A2
This pilot study describes the course of menopausal symptoms and the incidence of depression in 21 patients who were likely to become acutely estrogen deficient during treatment for breast cancer.
331-546
331
546
This pilot study describes the course of menopausal symptoms and the incidence of @SUBJECT$ @PREDICAT$ 21 @OBJECT$ who were likely to become acutely estrogen deficient during treatment for breast cancer.
Fact
preserve
716-725
716-725
T52
developed
PROCESS_OF
716
725
preserve
726-751
743-751
T47
major depressive disorder
MentalOrBehavioralDysfunction
726
751
preserve
701-709
701-709
T46
patients
PatientOrDisabledGroup
701
709
A4
Eight patients (38%) developed major depressive disorder, the majority within 6 months of starting treatment.
695-810
695
810
Eight @OBJECT$ (38%) @PREDICAT$ @SUBJECT$ , the majority within 6 months of starting treatment.
Probable
preserve
236-240
236-240
T23
risk
PREDISPOSES
236
240
preserve
158-169
162-169
T15
hot flashes
SignOrSymptom
158
169
preserve
244-275
267-275
T18
major depressive disorder
MentalOrBehavioralDysfunction
244
275
A7
The change of estrogen function, represented by amenorrhea or hot flashes, that results from breast cancer treatment may increase the risk of major depressive disorder in those women undergoing treatment for breast cancer.
96-330
96
330
The change of estrogen function, represented by amenorrhea or @SUBJECT$ , that results from breast cancer treatment may increase the @PREDICAT$ of @OBJECT$ in those women undergoing treatment for breast cancer.
Fact
preserve
63-65
63-65
T9
in
PROCESS_OF
63
65
preserve
53-62
53-62
T5
syndromes
DiseaseOrSyndrome
53
62
preserve
86-94
86-94
T7
patients
PatientOrDisabledGroup
86
94
A8
Iatrogenic acute estrogen deficiency and psychiatric syndromes in breast cancer patients.
0-95
0
95
Iatrogenic acute estrogen deficiency and psychiatric @SUBJECT$ @PREDICAT$ breast cancer @OBJECT$ .
Fact
preserve
833-836
833-836
T56
had
PROCESS_OF
833
836
preserve
837-846
837-846
T54
dysphoria
MentalOrBehavioralDysfunction
837
846
preserve
818-826
818-826
T53
patients
PatientOrDisabledGroup
818
826
A9
Twenty patients (95%) had dysphoria and/or insomnia.
811-869
811
869
Twenty @OBJECT$ (95%) @PREDICAT$ @SUBJECT$ and/or insomnia.
Fact
preserve
66-94
86-94
T8
breast cancer patients
PROCESS_OF
66
94
preserve
66-79
73-79
T6
breast cancer
NeoplasticProcess
66
79
preserve
86-94
86-94
T7
patients
PatientOrDisabledGroup
86
94
A10
Iatrogenic acute estrogen deficiency and psychiatric syndromes in breast cancer patients.
0-95
0
95
Iatrogenic acute estrogen deficiency and psychiatric syndromes in @SUBJECT$ @PREDICAT$ @OBJECT$ .
Fact
preserve
972-994
986-994
T68
breast cancer patients
PROCESS_OF
972
994
preserve
972-985
979-985
T62
breast cancer
NeoplasticProcess
972
985
preserve
986-994
986-994
T63
patients
PatientOrDisabledGroup
986
994
A11
While this is only pilot data, these data suggest that breast cancer patients whose treatment precipitates menopausal symptoms should be targeted for diagnosis of depression and treated if diagnosed.
911-1128
911
1,128
While this is only pilot data, these data suggest that @SUBJECT$ @PREDICAT$ @OBJECT$ whose treatment precipitates menopausal symptoms should be targeted for diagnosis of depression and treated if diagnosed.
Fact
preserve
63-65
63-65
T9
in
PROCESS_OF
63
65
preserve
17-36
26-36
T3
estrogen deficiency
DiseaseOrSyndrome
17
36
preserve
86-94
86-94
T7
patients
PatientOrDisabledGroup
86
94
A12
Iatrogenic acute estrogen deficiency and psychiatric syndromes in breast cancer patients.
0-95
0
95
Iatrogenic acute @SUBJECT$ and psychiatric syndromes @PREDICAT$ breast cancer @OBJECT$ .
Probable
preserve
236-240
236-240
T23
risk
PREDISPOSES
236
240
preserve
144-154
144-154
T14
amenorrhea
DiseaseOrSyndrome
144
154
preserve
244-275
267-275
T18
major depressive disorder
MentalOrBehavioralDysfunction
244
275
A14
The change of estrogen function, represented by amenorrhea or hot flashes, that results from breast cancer treatment may increase the risk of major depressive disorder in those women undergoing treatment for breast cancer.
96-330
96
330
The change of estrogen function, represented by @SUBJECT$ or hot flashes, that results from breast cancer treatment may increase the @PREDICAT$ of @OBJECT$ in those women undergoing treatment for breast cancer.
Fact
preserve
1330-1358
1353-1358
T68
vascular smooth muscle cells
PART_OF
1,330
1,358
preserve
1339-1358
1353-1358
T67
smooth muscle cells
Cell
1,339
1,358
preserve
1330-1338
1330-1338
T66
vascular
BodyPartOrganOrOrganComponent
1,330
1,338
A2
This increased reactivity to pressor factors may be due to an inadequate nitric oxide generation by vascular endothelium and to increased sodium and calcium concentration in vascular smooth muscle cells.
1144-1359
1,144
1,359
This increased reactivity to pressor factors may be due to an inadequate nitric oxide generation by vascular endothelium and to increased sodium and calcium concentration in @OBJECT$ @PREDICAT$ @SUBJECT$ .
Fact
preserve
1327-1329
1327-1329
T69
in
LOCATION_OF
1,327
1,329
preserve
1339-1358
1353-1358
T67
smooth muscle cells
Cell
1,339
1,358
preserve
1305-1312
1305-1312
T65
calcium
BiologicallyActiveSubstance
1,305
1,312
A3
This increased reactivity to pressor factors may be due to an inadequate nitric oxide generation by vascular endothelium and to increased sodium and calcium concentration in vascular smooth muscle cells.
1144-1359
1,144
1,359
This increased reactivity to pressor factors may be due to an inadequate nitric oxide generation by vascular endothelium and to increased sodium and @OBJECT$ concentration @PREDICAT$ vascular @SUBJECT$ .
Fact
preserve
1832-1841
1832-1841
T97
treatment
TREATS
1,832
1,841
preserve
1727-1749
1745-1749
T91
sodium-restricted diet
TherapeuticOrPreventiveProcedure
1,727
1,749
preserve
1866-1878
1866-1878
T96
hypertension
DiseaseOrSyndrome
1,866
1,878
A4
As to the therapeutic approach, the low-energy sodium-restricted diet associated with increased physical activity, represents the cornerstones of treatment for the obesity-related hypertension.
1674-1879
1,674
1,879
As to the therapeutic approach, the low-energy @SUBJECT$ associated with increased physical activity, represents the cornerstones of @PREDICAT$ for the obesity-related @OBJECT$ .
Fact
preserve
2092-2106
2098-2106
T108
obese patients
PROCESS_OF
2,092
2,106
preserve
2092-2097
2092-2097
T106
obese
DiseaseOrSyndrome
2,092
2,097
preserve
2098-2106
2098-2106
T107
patients
PatientOrDisabledGroup
2,098
2,106
A9
If this approach fails, the pharmacological treatment becomes necessary, and the use of the converting enzyme inhibitors seems to be the most appropriate choice of drug therapy for hypertensive obese patients.
1880-2107
1,880
2,107
If this approach fails, the pharmacological treatment becomes necessary, and the use of the converting enzyme inhibitors seems to be the most appropriate choice of drug therapy for hypertensive @SUBJECT$ @PREDICAT$ @OBJECT$ .
Fact
preserve
129-153
146-153
T13
overweight persons
PROCESS_OF
129
153
preserve
129-139
129-139
T6
overweight
SignOrSymptom
129
139
preserve
146-153
146-153
T7
persons
PopulationGroup
146
153
A10
While the prevalence of hypertension is clearly increased among the overweight persons, the pathophysiological mechanisms underlying this frequent association of obesity and hypertension are still poorly understood.
61-288
61
288
While the prevalence of hypertension is clearly increased among the @SUBJECT$ @PREDICAT$ @OBJECT$ , the pathophysiological mechanisms underlying this frequent association of obesity and hypertension are still poorly understood.
Fact
preserve
1327-1329
1327-1329
T69
in
LOCATION_OF
1,327
1,329
preserve
1339-1358
1353-1358
T67
smooth muscle cells
Cell
1,339
1,358
preserve
1294-1300
1294-1300
T64
sodium
BiologicallyActiveSubstance
1,294
1,300
A13
This increased reactivity to pressor factors may be due to an inadequate nitric oxide generation by vascular endothelium and to increased sodium and calcium concentration in vascular smooth muscle cells.
1144-1359
1,144
1,359
This increased reactivity to pressor factors may be due to an inadequate nitric oxide generation by vascular endothelium and to increased @OBJECT$ and calcium concentration @PREDICAT$ vascular @SUBJECT$ .
Fact
preserve
851-896
887-896
T68
celecoxib, a highly selective COX-2 inhibitor
higher_than
851
896
preserve
851-860
851-860
T45
celecoxib
OrganicChemical
851
860
preserve
919-926
919-926
T48
placebo
MedicalDevice
919
926
A1
Preliminary data suggest that celecoxib, a highly selective COX-2 inhibitor, is superior to placebo and similar to traditional NSAIDs in the short-term treatment of pain due to osteoarthritis, although it has been associated with adverse effects such as headache, change in bowel habits, abdominal discomfort, and dizziness.
814-1163
814
1,163
Preliminary data suggest that @SUBJECT$ @PREDICAT$ , is superior to @OBJECT$ and similar to traditional NSAIDs in the short-term treatment of pain due to osteoarthritis, although it has been associated with adverse effects such as headache, change in bowel habits, abdominal discomfort, and dizziness.
Fact
preserve
1600-1602
1600-1602
T104
as
same_as
1,600
1,602
preserve
1550-1559
1550-1559
T93
rofecoxib
OrganicChemical
1,550
1,559
preserve
1615-1621
1615-1621
T95
NSAIDs
PharmacologicSubstance
1,615
1,621
A2
In the treatment of osteoarthritis, rofecoxib has been shown to be as effective as traditional NSAIDs and may cause fewer endoscopically documented ulcers, but its complete adverse-effect profile is not known.
1514-1735
1,514
1,735
In the treatment of osteoarthritis, @SUBJECT$ has been shown to be as effective @PREDICAT$ traditional @OBJECT$ and may cause fewer endoscopically documented ulcers, but its complete adverse-effect profile is not known.
Fact
preserve
997-1009
997-1000
T66
due to
CAUSES
997
1,009
preserve
1010-1024
1010-1024
T54
osteoarthritis
DiseaseOrSyndrome
1,010
1,024
preserve
992-996
992-996
T53
pain
SignOrSymptom
992
996
A3
Preliminary data suggest that celecoxib, a highly selective COX-2 inhibitor, is superior to placebo and similar to traditional NSAIDs in the short-term treatment of pain due to osteoarthritis, although it has been associated with adverse effects such as headache, change in bowel habits, abdominal discomfort, and dizziness.
814-1163
814
1,163
Preliminary data suggest that celecoxib, a highly selective COX-2 inhibitor, is superior to placebo and similar to traditional NSAIDs in the short-term treatment of @OBJECT$ @PREDICAT$ @SUBJECT$ , although it has been associated with adverse effects such as headache, change in bowel habits, abdominal discomfort, and dizziness.
Fact
preserve
1600-1602
1600-1602
T103
as
compared_with
1,600
1,602
preserve
1550-1559
1550-1559
T93
rofecoxib
OrganicChemical
1,550
1,559
preserve
1615-1621
1615-1621
T95
NSAIDs
PharmacologicSubstance
1,615
1,621
A4
In the treatment of osteoarthritis, rofecoxib has been shown to be as effective as traditional NSAIDs and may cause fewer endoscopically documented ulcers, but its complete adverse-effect profile is not known.
1514-1735
1,514
1,735
In the treatment of osteoarthritis, @SUBJECT$ has been shown to be as effective @PREDICAT$ traditional @OBJECT$ and may cause fewer endoscopically documented ulcers, but its complete adverse-effect profile is not known.
Probable
preserve
771-776
771-776
T42
cause
CAUSES
771
776
preserve
629-634
629-634
T30
NSAID
PharmacologicSubstance
629
634
preserve
800-812
805-812
T38
side effects
PathologicFunction
800
812
A5
Theoretically, an NSAID that inhibits COX-2 selectively should decrease inflammation but not influence normal physiologic functions and thus should cause fewer gastrointestinal side effects.
611-813
611
813
Theoretically, an @SUBJECT$ that inhibits COX-2 selectively should decrease inflammation but not influence normal physiologic functions and thus should @PREDICAT$ fewer gastrointestinal @OBJECT$ .
Fact
preserve
1521-1530
1521-1530
T105
treatment
TREATS
1,521
1,530
preserve
1615-1621
1615-1621
T95
NSAIDs
PharmacologicSubstance
1,615
1,621
preserve
1534-1548
1534-1548
T92
osteoarthritis
DiseaseOrSyndrome
1,534
1,548
A6
In the treatment of osteoarthritis, rofecoxib has been shown to be as effective as traditional NSAIDs and may cause fewer endoscopically documented ulcers, but its complete adverse-effect profile is not known.
1514-1735
1,514
1,735
In the @PREDICAT$ of @OBJECT$ , rofecoxib has been shown to be as effective as traditional @SUBJECT$ and may cause fewer endoscopically documented ulcers, but its complete adverse-effect profile is not known.
Fact
preserve
1220-1222
1220-1222
T80
as
same_as
1,220
1,222
preserve
1164-1173
1164-1173
T69
Celecoxib
OrganicChemical
1,164
1,173
preserve
1235-1241
1235-1241
T71
NSAIDs
PharmacologicSubstance
1,235
1,241
A8
Celecoxib also has been shown to be as effective as traditional NSAIDs in the treatment of rheumatoid arthritis, but it may cause fewer adverse effects, including endoscopically documented ulcers.
1164-1380
1,164
1,380
@SUBJECT$ also has been shown to be as effective @PREDICAT$ traditional @OBJECT$ in the treatment of rheumatoid arthritis, but it may cause fewer adverse effects, including endoscopically documented ulcers.
Fact
preserve
851-896
887-896
T64
celecoxib, a highly selective COX-2 inhibitor
ISA
851
896
preserve
851-860
851-860
T45
celecoxib
OrganicChemical
851
860
preserve
881-896
887-896
T46
COX-2 inhibitor
OrganicChemical
881
896
A9
Preliminary data suggest that celecoxib, a highly selective COX-2 inhibitor, is superior to placebo and similar to traditional NSAIDs in the short-term treatment of pain due to osteoarthritis, although it has been associated with adverse effects such as headache, change in bowel habits, abdominal discomfort, and dizziness.
814-1163
814
1,163
Preliminary data suggest that @SUBJECT$ @PREDICAT$ @OBJECT$ , is superior to placebo and similar to traditional NSAIDs in the short-term treatment of pain due to osteoarthritis, although it has been associated with adverse effects such as headache, change in bowel habits, abdominal discomfort, and dizziness.